Robert Stevens
Direttore Tecnico/Scientifico/R&S presso CorneaGen, Inc.
Profilo
Robert J.
Stevens is currently a Senior Vice President-Research & Development at CorneaGen, Inc. He previously worked as a Director at Acucela, Inc. Stevens received his undergraduate and graduate degrees from the University of Washington.
Posizioni attive di Robert Stevens
Società | Posizione | Inizio |
---|---|---|
CorneaGen, Inc.
CorneaGen, Inc. Medical SpecialtiesHealth Technology CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Robert Stevens
Società | Posizione | Fine |
---|---|---|
ACUCELA INC | Direttore/Membro del Consiglio | - |
Formazione di Robert Stevens
University of Washington | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
CorneaGen, Inc.
CorneaGen, Inc. Medical SpecialtiesHealth Technology CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA. | Health Technology |
Acucela, Inc.
Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Robert Stevens